The United Kingdom and the United States have reached a key trade agreement that will ensure zero tariffs on UK drug exports going into the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to increase funding on drugs through the NHS. This commitment ensures that duties on these vital goods will stay at nothing for a timeframe of the next three years.
This development comes after recent threats to dramatically increase import taxes on patented drug products, with increases floated reaching one hundred percent.
"This arrangement between the United Kingdom reinforces the global environment for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest exports to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of September, the UK exported medicines valued at billions to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This deal safeguards employment, stimulates funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The agreement includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to increase overall public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. Last year, repayments topped 20%.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by claims that American consumers were charged a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while substantial investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had shrunk as a percentage of its overall budget over the last ten years.
